ABIOMED INC ABIOMED ORD SHS 

$381.02
38
+$0.00+0% Thursday 16:24

统计

当日最高
-
当日最低
-
52周高点
-
52周低点
-
成交量
-
平均成交量
-
市值
0
市盈率
1.28
股息率
-
股息
-

财报

30Oct预期
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
1.19
1.57
1.94
2.32
预期EPS
不适用
实际EPS
不适用

财务

13.23%利润率
有盈利
2016
2017
2018
2019
2020
2021
1.03B营收
136.51M净利润

竞争对手

此列表为基于近期市场事件的分析。并非投资建议。

关于

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Show more...
首席执行官
Mr. Michael R. Minogue
员工
2003
国家
美国
ISIN
US0036541003
WKN
000873886

上市

0 Comments

分享你的想法

FAQ

ABIOMED INC ABIOMED ORD SHS 今天的股价是多少?
0H7S.LSE 当前价格为 $381.02 USD,过去 24 小时上涨了 +0%。在图表上更密切关注 ABIOMED INC ABIOMED ORD SHS 股价表现。
ABIOMED INC ABIOMED ORD SHS 的股票代码是什么?
根据交易所不同,股票代码可能会有所不同。例如,在 London Exchange 交易所,ABIOMED INC ABIOMED ORD SHS 的股票以代码 0H7S.LSE 进行交易。
ABIOMED INC ABIOMED ORD SHS 去年的营收是多少?
ABIOMED INC ABIOMED ORD SHS 去年的营收为 1.03BUSD。
ABIOMED INC ABIOMED ORD SHS 去年的净利润是多少?
0H7S.LSE 去年的净收益为 136.51MUSD。
ABIOMED INC ABIOMED ORD SHS 有多少名员工?
截至九月 09, 2026,公司共有2,003名员工。
ABIOMED INC ABIOMED ORD SHS 属于哪个行业?
ABIOMED INC ABIOMED ORD SHS从事于其他行业。
ABIOMED INC ABIOMED ORD SHS 何时完成拆股?
ABIOMED INC ABIOMED ORD SHS 最近没有进行任何拆股。
ABIOMED INC ABIOMED ORD SHS 的总部在哪里?
ABIOMED INC ABIOMED ORD SHS 的总部位于 美国 的 Danvers。